Table 1.

Pretransplantation characteristics of patients

Patient no.SexAge, yType of MSEDSSDisease duration, moPrior therapy
1 F 34 SP 8.0 163 IFN-1β, GA
2 F 49 SP 6.5 277 INF-1β, MPSE, bee stings
3 M 37 PP 6.0 10 MPSE
4 F 46 RR 7.0 97 IFN-α, IFN-1β, GA, MPSE
5 M 35 SP 6.0 24 IFN-1α, IFN1β, GA
6 F 37 SP 6.0 69 IFN-1α, IFN-1β, GA
7 F 51 SP 7.0 69 IFN-1β
8 F 48 SP 8.0 79 IFN-1β
9 F 57 SP 7.0 82 IFN-1α, IFN1β, GA
10 M 51 PP 6.5 84 IFN-α, IFN-1β, MPSE
11 F 47 SP 8.0 107 IFN-1α, IFN1β, GA
12 M 38 SP 6.5 119 IFN-1α, IFN1β
13 F 29 SP 6.5 138 IFN-α, IFN-1β, GA, MPSE
14 M 43 PP 7.0 110 IFN-1β
15 M 27 PP 7.5 48 IFN-1β, GA
16 M 60 SP 7.5 50 IFN-α, IFN-1β, MPSE
17 F 44 SP 7.5 188 IFN-α, GA, Ctx
18 F 47 SP 7.5 149 IFN-1β, Mtx
19 M 29 SP 5.0 144 IFN-α
20 M 36 PP 6.5 48 MPSE
21 M 45 SP 8.0 83 IFN-1β, GA
22 M 44 PP 6.5 94 IFN-α, IFN-1β, Imuran
23 M 52 PP 5.0 49 IFN-α
24 M 28 PP 7.0 12 IFN-α, IFN-1β, IVIG, Prd, Nv
25 F 47 SP 8.0 179 IFN-1β, Ctx, Prd
26 M 41 SP 7.0 195 IFN-α, IFN-1β, IVIG
Median 41 7.0 84
  • F indicates female; SP, secondary progressive; IFN-β interferon-β (Betaseron); GA, glatiramer acetate; MPSE, methylprednisolone; M, male; PP, primary progressive; RR, relapsing-remitting; IFN-α, interferon-α (Avonex); Ctx, cyclophosphamide; Mtx, methotrexate; IVIG, intravenous immunoglobulin; Prd, prednisone; and Nv, mitoxantrone.